Ziftomenib for relapsed AML with NPM1 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with confirmed acute myeloid leukemia (AML) that has relapsed (come back) or is refractory (not responding to treatment)
- Your AML must have an NPM1 mutation (a specific genetic change) confirmed by testing
- You must have either no standard treatment options available or have chosen not to pursue standard therapy
- Your white blood cell count must be 30,000 or lower (medication can help lower this if needed)
- Your organs (heart, liver, kidneys) must be functioning well enough for the study
- You cannot be pregnant, nursing, or unwilling to use effective birth control during and after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests a combination of two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. It's designed for those whose leukemia cells have a specific genetic change (KMT2A rearrangement or NPM1 mutation).
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.